Proposal to list ostomy products supplied by Omnigon Pty Ltd

Hospital devices

Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of Ostomy Products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019, through a listing agreement with Omnigon Pty Ltd (“Omnigon”).

What we are proposing

PHARMAC is seeking feedback on a proposal to list a range of Ostomy Products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019, through a listing agreement with Omnigon Pty Ltd (“Omnigon”).

Consultation closes at 4pm on Friday, 14 December 2018 and feedback can be emailed to josh.wiles@pharmac.govt.nz.

What would the effect be?

From 1 February 2019, Omnigon’s range of Ostomy Products would be listed under the proposed national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of Ostomy Products.

The Agreement would supersede any existing DHB contracts with Omnigon for the Ostomy Products included in the Agreement.  Any Ostomy Products listed in the Agreement and purchased by a DHB would be at the price, terms and conditions stated in the Agreement, effective from the listing date on the Pharmaceutical Schedule.

As part of the Agreement, Omnigon would provide training and education that would be tailored to the needs of individual DHBs.

Who we think will be interested

  • Suppliers and wholesalers
  • DHB staff:
    • stoma nurses
    • clinical staff in a range of inpatient, outpatient and community settings where Ostomy Products are used
    • procurement and supply chain personnel
  • Users of Ostomy Products provided by DHBs

About Ostomy Products

Ostomy Products are used in hospital and community settings, from short to long-term use.

Ostomy Products include one and two-piece pouching systems to manage stoma drainage, for example colostomy or urostomy drainage, as well as a range of skin protection products.

Why we are proposing this

In May 2018 PHARMAC issued a Request for Proposals (“RFP”) for the supply of urology, ostomy and continence products.

The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC is working with a range of suppliers to seek provisional agreements and this proposal is the latest to arise from that process. We expect to consult on further proposed agreements in the urology, ostomy and continence categories over the coming months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Omnigon for a range of Ostomy Products. Pricing and a full product list has been made available to appropriate DHB personnel.

This proposal would result in listing 990 Ostomy Products on the Pharmaceutical Schedule.

The brands included in the Agreement are:

  • Aurum
  • Aurum 2
  • B.Braun High Flow Collector
  • B.Braun Stoma Care Belt
  • B.Braun Urimed Overnight Bag
  • Diamond Plus Briefs
  • Diamond Plus Support Waistbands
  • Diamond Plus Unisex Boxers
  • Eakin Cohesive Paste
  • Eakin Cohesive Seal
  • Eakin Cohesive Skin Barrier
  • Eakin Dot
  • Eakin Pelican
  • Eakin Pelican Belt
  • Eakin Perform
  • Eakin Protect
  • Eakin Release
  • Eakin Surround
  • Eakin Wound Pouch
  • Flair 2
  • Flair Active
  • Flexima
  • Flexima 3S
  • Flexima Active
  • Flexima Key
  • Flexima Uro Silk
  • IsoFlex Support Belts
  • KoolKnit Support Belts
  • Men's Support Pants
  • Support Briefs For Her
  • Total Control Support Belts
  • Welland Adhesive Remover
  • Welland Barrier Film
  • Welland Belt
  • Welland Hydroframe
  • Welland HyperSeal
  • Welland Night Drainage Bag
  • Welland Stoma Paste
  • Welland Stoma Powder
  • Welland Ultraframe

To provide feedback

Send us an email: josh.wiles@pharmac.govt.nz by 4pm Friday 14 December 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.